Superior Court Upholds $70M Risperdal Verdict
A Pennsylvania Superior Court has rejected Johnson & Johnson’s appeal of a 2016 $70 million verdict awarded to a 20 year-old Tennessee man, Andrew Yount (A.Y.) who developed gynecomastia after taking the antipsychotic drug Risperdal since he was 4-1/2 years old. Gynecomastia is an irreversible condition caused by an increase in the hormone prolactin and […]
Positive Developments in Risperdal Litigation in August
Several positive developments this month for young men injured from taking the Risperdal. Risperdal is an anti-psychotic drug manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals. The drug’s side effects included gynecomastia, the growth of female-like breast in young boys. $2.5M Jury Verdict Stands The Supreme Court of Pennsylvania has declined to hear an appeal of […]
